Skip to main content
TipRanks
Go Ultimate75% OFF

Lawrence Wennogle Insider Profile

4 Followers

Lawrence Wennogle, former Vice President, Drug Discovery at Intra-Cellular Therapies, holds 126.50K shares in Intra-Cellular Therapies (Ticker: ITCI).

Lawrence Wennogle's Trading History

ITCI
Intra-Cellular Therapies
Jun 09, 2015―Uninformative Sell671.00K$16.68M
ITCI
DateTransactionAmountNo. of SharesPrice per ShareProfitLink to Report
Jun 09, 2015Uninformative Sell$671.00K25,000$26.84―
May 20, 2015Informative Buy$58.25K47,500$1.22+44.60%
Oct 17, 2014Uninformative Sell$77.28K5,152$15.00―
Oct 15, 2014Uninformative Sell$54.06K3,604$15.00―
Oct 10, 2014Uninformative Sell$71.17K4,745$15.00―

You May Also Like

Lawrence Wennogle insider profile FAQ

What is the percentage of profitable transactions made by Lawrence Wennogle?
The percentage of profitable transactions made by Lawrence Wennogle is 100%.
What is the average return per transaction made by Lawrence Wennogle?
The average return per transaction made by Lawrence Wennogle is 42.30%.
What stocks does Lawrence Wennogle hold?
Lawrence Wennogle holds: ITCI stocks.
What was Lawrence Wennogle’s latest transaction?
Lawrence Wennogle’s latest transaction was an Uninformative Sell of $671.00K.
What was Lawrence Wennogle's most profitable transaction?
Lawrence Wennogle’s most profitable transaction was an Informative Buy of ITCI stock on July 22, 2014. The return on the trade was 114.30%.
What is Lawrence Wennogle's role in Intra-Cellular Therapies?
Lawrence Wennogle's role in Intra-Cellular Therapies is Vice President, Drug Discovery.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.